Literature DB >> 22294110

[Histoplasmosis: uncommon opportunistic infection in a patient with HIV infection].

M Escher1, T M Kainikkara, A Grabner, G Ott, E F Stange, K R Herrlinger.   

Abstract

HISTORY AND ADMISSION
FINDINGS: A 19-year-old HIV-positive man was admitted with fever of unknown origin and poor general condition. Antiretroviral therapy had been stopped by the patient eight months prior to admission. INVESTIGATIONS: Laboratory tests revealed pancytopenia, high viral load and low count of T-helper cells (13/µl). Computer tomography of the thorax showed small patchy infiltrations. Extensive examinations (microbiology, laboratory tests, multiple investigations) revealed no pathogen. Liver biopsy proved disseminated histoplasmosis. TREATMENT AND COURSE: Liposomal amphotericin B was started and switched to oral itraconazole after 14 days with itraconazole. With this treatment the patient condition improved and fever stopped. T-helper cells increased and the patient was discharged.
CONCLUSION: Disseminated histoplasmosis as an AIDS-defining opportunistic infection is uncommon (particularly as the patient had not been abroad in the last four years) and can be a life-threatening complication. Diagnosis must be confirmed by invasive methods especially in patients with compromised immune status and rapid clinical progression. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22294110     DOI: 10.1055/s-0031-1298872

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  Disseminated histoplasmosis in an HIV patient with CD4 count of 1 cell/µL.

Authors:  Sri Harsha Tella; Ahmed Abuzaid
Journal:  BMJ Case Rep       Date:  2014-08-19

2.  Colonic involvement in disseminated histoplasmosis of an immunocompetent adult: case report and literature review.

Authors:  Biwei Yang; Lixia Lu; Dajiang Li; Li Liu; Libin Huang; Liyu Chen; Hong Tang; Lichun Wang
Journal:  BMC Infect Dis       Date:  2013-03-20       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.